Sarcosine in Urine after Digital Rectal Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours

European Urology

Volumn 58, Issue 1, 2010, Pages 12-18

  Jentzmik, Florian ^a   Stephan, Carsten ^a   Miller, Kurt ^a   Schrader, Mark ^a   Erbersdobler, Andreas ^a   Kristiansen, Glen ^b   Lein, Michael ^a,c   Jung, Klaus ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Berlin Institute for Urologic Research   (Germany)

Author keywords

Metabolite profiling; Prostate cancer; Prostate cancer detection; Prostate specific antigen; Sarcosine in urine

Indexed keywords

BIOLOGICAL MARKER; CREATININE; PROSTATE SPECIFIC ANTIGEN; SARCOSINE;

ADULT; AGED; AMINO ACID ANALYSIS; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; DISEASE COURSE; EARLY DIAGNOSIS; GAS CHROMATOGRAPHY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; ORGAN SIZE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; URINALYSIS;

AGED; COHORT STUDIES; CREATININE; DIGITAL RECTAL EXAMINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGAN SIZE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SARCOSINE; TUMOR MARKERS, BIOLOGICAL;

EID: 77952880168     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.01.035     Document Type: Article

References (21)

1. Spratlin J.L., Serkova N.J., and Eckhardt S.G. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res 15 (2009) 431-440
2. Osl M., Dreiseitl S., Pfeifer B., et al. A new rule-based algorithm for identifying metabolic markers in prostate cancer using tandem mass spectrometry. Bioinformatics 24 (2008) 2908-2914
3. Kim K., Aronov P., Zakharkin S.O., et al. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics 8 (2009) 558-570
4. Sreekumar A., Poisson L.M., Rajendiran T.M., et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457 (2009) 910-914
5. Abate-Shen C., and Shen M.M. Diagnostics: the prostate-cancer metabolome. Nature 457 (2009) 799-800
6. Kuehn B.M. Promising marker found for deadly prostate cancer. JAMA 301 (2009) 1008
7. Couzin J., and Biomarkers. Metabolite in urine may point to high-risk prostate cancer. Science 323 (2009) 865
8. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279 (1998) 1542-1547
9. Finne P., Auvinen A., Määttänen L., et al. Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 μg per liter. Eur Urol 54 (2008) 362-370
10. Kattan M.W. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 95 (2003) 634-635
11. Deras I.L., Aubin S.M., Blase A., et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 179 (2008) 1587-1592
12. Schröder B. Evaluating the predictive performance of species distribution models. Institute of Geoecology, Potsdam University, Web site. http://brandenburg.geoecology.uni-potsdam.de/users/schroeder/download.html. Accessed October 6, 2009.
13. Faul F., Erdfelder E., Lang A.G., and Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39 (2007) 175-191
14. Stephan C., Klaas M., Müller C., Schnorr D., Loening S.A., and Jung K. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem 52 (2006) 59-64
15. Jung K. Enzyme activities in urine: how should we express their excretion? A critical literature review. Eur J Clin Chem Clin Biochem 29 (1991) 725-729
16. Mitchell A.D., and Benevenga N.J. Importance of sarcosine formation in methionine methyl carbon oxidation in the rat. J Nutr 106 (1976) 1702-1713
17. Mudd S.H., Brosnan J.T., Brosnan M.E., et al. Methyl balance and transmethylation fluxes in humans. Am J Clin Nutr 85 (2007) 19-25
18. De Kok J.B., Verhaegh G.W., Roelofs R.W., et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 62 (2002) 2695-2698
19. Sokoll L.J., Ellis W., Lange P., et al. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta 389 (2008) 1-6
20. Mi P.E., Lee E., Jin J.H., Oh E., Lee J., and Lee J.S. Inter- and intra-individual variations of urinary endogenous metabolites in healthy male college students using (1)H NMR spectroscopy. Clin Chem Lab Med 47 (2009) 188-194
21. Jung K. Re: the metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. Eur Urol 54 (2008) 1198-1199